Malta - engelsk - Medicines Authority

boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - goserelin acetate - implant - goserelin acetate 10.8 milligram(s) - endocrine therapy

Malta - engelsk - Medicines Authority

boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - goserelin acetate - implant - goserelin acetate 3.6 milligram(s) - endocrine therapy

Malta - engelsk - Medicines Authority

uab boston biopharma lt v.a. graiciuno g. 6-2 vilniaus m. sav. lt-02241, lithuania - goserelin acetate - implant - goserelin acetate 3.6 mg - endocrine therapy

Malta - engelsk - Medicines Authority

uab boston biopharma lt v.a. graiciuno g. 6-2 vilniaus m. sav. lt-02241, lithuania - goserelin acetate - implant - goserelin acetate 10.8 mg - endocrine therapy

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

luye pharma ag (8028156) - goserelinacetat (1:x) ((mit angaben zum essigsäure-gehalt)) - implantat - teil 1 - implantat; goserelinacetat (1:x) ((mit angaben zum essigsäure-gehalt)) (24071) 4 milligramm

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m plus) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, astrazeneca goserelin shrinks the lesions and reduces the symptoms, including pain. astrazeneca goserelin also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. endometrial thinning: use as an endometrial thinning agent prior to endometrial ablation. assisted reproduction: pituitary down regulation in preparation for controlled ovarian superstimulation.

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

euro registratie collectief b.v. van der giessenweg 5 2921 lp krimpen a/d ijssel - goserelineacetaat samenstelling overeenkomend met ; ; gosereline - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

euro registratie collectief b.v. van der giessenweg 5 2921 lp krimpen a/d ijssel - goserelineacetaat samenstelling overeenkomend met ; ; gosereline - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

euro registratie collectief b.v. van der giessenweg 5 2921 lp krimpen a/d ijssel - goserelineacetaat samenstelling overeenkomend met ; ; gosereline - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dr. fisher farma b.v. - goserelineacetaat samenstelling overeenkomend met; gosereline; - implantatietablet - goserelin